5453-07-6

Basic information

• Product Name: 3-amino-5-methyl-1H-pyrazole-4-carbonitrile
• Synonyms: 3-amino-5-methyl-1H-pyrazole-4-carbonitrile;5-Amino-4-cyano-3-methylpyrazole;3-azanyl-5-methyl-1H-pyrazole-4-carbonitrile;3-Amino-5-methylpyrazole-4-carbonitrile;5-Amino-3-methylpyrazole-4-carbonitrile;5-Amino-4-cyano-3-methyl-1H-pyrazole;NSC 19055
• CAS NO: 5453-07-6
• Molecular Formula: C₅H₆N₄
• Molecular Weight: 122.13
• Product Categories: Amines;blocks;Carboxes
• Mol File: 5453-07-6.mol
• Article Data: 15

Chemical Properties

• Melting Point: 162℃
• Boiling Point: 429.4°C at 760 mmHg
• Flash Point: 213.5°C
• Appearance: /
• Density: 1.32
• Vapor Pressure: 1.41E-07mmHg at 25°C
• Refractive Index: 1.596
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• CAS DataBase Reference: 3-amino-5-methyl-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-5-methyl-1H-pyrazole-4-carbonitrile(5453-07-6)
• EPA Substance Registry System: 3-amino-5-methyl-1H-pyrazole-4-carbonitrile(5453-07-6)

Safety Data

• Hazardous Substances Data: 5453-07-6(Hazardous Substances Data)

Usage

General Description

3-amino-5-methyl-1H-pyrazole-4-carbonitrile is a chemical compound with the molecular formula C5H6N4. It is a pyrazole derivative with a nitrile group attached to the carbon at position 4 of the pyrazole ring, as well as amino and methyl groups at positions 3 and 5, respectively. 3-amino-5-methyl-1H-pyrazole-4-carbonitrile has potential applications in the pharmaceutical industry, particularly in the development of new drugs and pharmaceutical intermediates. Its unique structure and properties make it useful for research and development purposes in the field of medicinal chemistry. Additionally, it may also have potential uses in other industries such as agrochemicals and material science. Overall, 3-amino-5-methyl-1H-pyrazole-4-carbonitrile is a versatile compound with diverse potential applications.

InChI:InChI=1/C5H6N4/c1-3-4(2-6)5(7)9-8-3/h1H3,(H3,7,8,9)

Upstream product

• 5417-82-3 (1-ethoxyethylidene)malononitrile 
• 75-36-5 acetyl chloride 
• 109-77-3 malononitrile 
• 2644-70-4 hydrazine hydrochloride 
• 5515-16-2 2-(methoxyethylidene)propanedinitrile 
• 1187-11-7 acetylmalonodinitrile 
• 1202180-98-0 benzyl 5-amino-4-cyano-3-methyl-1H-pyrazole-1-carboxylate 

Downstream Products

• 1202181-02-9 7-methyl-4-oxo-3-phenethyl-3,4-dihydropyrazolo[5,1-d]-[1,2,3,5]tetrazine-8-carbonitrile 
• 1202180-99-1 7-methyl-4-oxo-3-phenyl-3,4-dihydropyrazolo[5,1-d][1,2,3,5]tetrazine-8-carbonitrile 
• 1202181-01-8 3-benzyl-7-methyl-4-oxo-3,4-dihydropyrazolo[5,1-d]-[1,2,3,5]tetrazine-8-carbonitrile 
• 1693-94-3 2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one 
• 1211522-68-7 4,6-dichloro-3-methyl-1H-pyrazolo[3,4-d]pyrimidine 
• 1384973-03-8 5-(2,3,6-trifluorophenyl)-4-imino-3-methyl-4,5-dihydro-1H-pyrazolo-[3,4-d]pyrimidine-6(7H)-thione 
• 1384973-01-6 5-(2,6-difluorophenyl)-4-imino-3-methyl-4,5-dihydro-1H-pyrazolo-[3,4-d]pyrimidine-6(7H)-thione 
• 1384972-99-9 4-imino-3-methyl-5-phenyl-4,5-dihydro-1H-pyrazolo-[3,4-d]pyrimidine-6(7H)-thione 

Relevant articles and documents

Pyrazolo[3,4-d]pyrimidine derivatives as irreversible Bruton's tyrosine kinase inhibitors

4,6-Disubstituted pyrazolo[3,4-d]pyrimidine derivatives were explored as irreversible Bruton's tyrosine kinase (BTK) inhibitors. The structure–activity relationship was established with over 20 derivatives synthesized to determine initial hit compounds, based on activities against BTK enzyme and TMD8 cells. It turns out that introducing 1-acrylamido-4-aminopiperdine (1b) at the C4 position of pyrazolopyrimidine as in 5e, and 3-acrylamido-aniline (1j) as 4-position substituent, such as in 9d, 10d, and 10e, delivered potent in vitro enzyme activities as well as TMD8 cell-based cytotoxicities. Considering kinase selectivity profiles, 5e was selected for in vivo efficacy studies with a murine xenograft model using TMD8 cells, where 5e exhibited moderate tumor growth inhibition activities. Further optimization of 5e and 9d may lead to clinically useful compounds to overcome B-cell-mediated hematologic cancers.

Fused-pyrimidine derivatives, preparation method thereof, and pharmaceutical composition for use in preventing or treating Bruton's tyrosine kinase activity related diseases containing the same as an active ingredient

The present invention relates to a conjugated pyrimidine derivative, a method for manufacturing the same, and a pharmaceutical composition for preventing or treating Bruton′s tyrosine kinase activity-related diseases containing the same as an active ingredient. The conjugated pyrimidine derivative according to the present invention is excellent in the ability to inhibit the activity of Bruton′s tyrosine kinase or TMD80, and thus can be usefully used for prevention or treatment of diseases related to Bruton′s tyrosine kinase activity, particularly cancer or autoimmune diseases.COPYRIGHT KIPO 2019

3-cyanopyrazolopyrimidine [1,5-a] derivative as well as preparation method and application thereof

The invention belongs to the field of chemical medicines and specifically relates to a 3-cyanopyrazolopyrimidine [1,5-a] derivative as well as a preparation method and application thereof. The invention provides the 3-cyanopyrazolopyrimidine [1,5-a] derivative, and the structure of the 3-cyanopyrazolopyrimidine [1,5-a] derivative is shown as a formula I. The invention further provides the preparation method and the application of the 3-cyanopyrazolopyrimidine [1,5-a] derivative. (The formula I is shown in the description).